Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD

By Beeh Kai-Michael   Wagner Frank   Khindri Sanjeev   Drollmann Anton Franz  

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 8, Iss. 5, 2011-09 ,pp. : 340-345

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients

By Van de Maele Boudewijn   Fabbri Leonardo M.   Martin Carmen   Horton Rachael   Dolker Michael   Overend Tim  

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 7, Iss. 6, 2010-12 ,pp. : 418-427

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of Indacaterol, a New 24-hour β 2-Agonist, in Patients with Asthma: A Dose-Ranging Study

By Kanniess Frank   Boulet Louis-Philippe   Pierzchala Wladyslaw   Cameron Ray   Owen Roger   Higgins Mark  

Journal of Asthma, Vol. 45, Iss. 10, 2008-12 ,pp. : 887-892

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of Indacaterol 75 μg Once-Daily on Dyspnea and Health Status: Results of Two Double-Blind, Placebo-Controlled 12-Week Studies

By Gotfried Mark H.   Kerwin Edward M.   Lawrence David   Lassen Cheryl   Kramer Benjamin  

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 9, Iss. 6, 2012-11 ,pp. : 629-636

Informa Healthcare

Access to resources Recommend Favorite